These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
197 related articles for article (PubMed ID: 19330836)
1. Lysyl oxidase-like 2 promotes migration in noninvasive breast cancer cells but not in normal breast epithelial cells. Hollosi P; Yakushiji JK; Fong KS; Csiszar K; Fong SF Int J Cancer; 2009 Jul; 125(2):318-27. PubMed ID: 19330836 [TBL] [Abstract][Full Text] [Related]
2. Lysyl oxidase-like 2 expression is increased in colon and esophageal tumors and associated with less differentiated colon tumors. Fong SF; Dietzsch E; Fong KS; Hollosi P; Asuncion L; He Q; Parker MI; Csiszar K Genes Chromosomes Cancer; 2007 Jul; 46(7):644-55. PubMed ID: 17394133 [TBL] [Abstract][Full Text] [Related]
3. MCF-7 cells expressing nuclear associated lysyl oxidase-like 2 (LOXL2) exhibit an epithelial-to-mesenchymal transition (EMT) phenotype and are highly invasive in vitro. Moon HJ; Finney J; Xu L; Moore D; Welch DR; Mure M J Biol Chem; 2013 Oct; 288(42):30000-30008. PubMed ID: 24014025 [TBL] [Abstract][Full Text] [Related]
4. Secreted LOXL2 is a novel therapeutic target that promotes gastric cancer metastasis via the Src/FAK pathway. Peng L; Ran YL; Hu H; Yu L; Liu Q; Zhou Z; Sun YM; Sun LC; Pan J; Sun LX; Zhao P; Yang ZH Carcinogenesis; 2009 Oct; 30(10):1660-9. PubMed ID: 19625348 [TBL] [Abstract][Full Text] [Related]
5. Lysyl oxidase-like 2 as a new poor prognosis marker of squamous cell carcinomas. Peinado H; Moreno-Bueno G; Hardisson D; Pérez-Gómez E; Santos V; Mendiola M; de Diego JI; Nistal M; Quintanilla M; Portillo F; Cano A Cancer Res; 2008 Jun; 68(12):4541-50. PubMed ID: 18559498 [TBL] [Abstract][Full Text] [Related]
6. Dormant tumor cells expressing LOXL2 acquire a stem-like phenotype mediating their transition to proliferative growth. Weidenfeld K; Schif-Zuck S; Abu-Tayeh H; Kang K; Kessler O; Weissmann M; Neufeld G; Barkan D Oncotarget; 2016 Nov; 7(44):71362-71377. PubMed ID: 27655685 [TBL] [Abstract][Full Text] [Related]
7. LOXL2-mediated matrix remodeling in metastasis and mammary gland involution. Barker HE; Chang J; Cox TR; Lang G; Bird D; Nicolau M; Evans HR; Gartland A; Erler JT Cancer Res; 2011 Mar; 71(5):1561-72. PubMed ID: 21233336 [TBL] [Abstract][Full Text] [Related]
8. Lysyl Oxidase-like Protein LOXL2 Promotes Lung Metastasis of Breast Cancer. Salvador F; Martin A; López-Menéndez C; Moreno-Bueno G; Santos V; Vázquez-Naharro A; Santamaria PG; Morales S; Dubus PR; Muinelo-Romay L; López-López R; Tung JC; Weaver VM; Portillo F; Cano A Cancer Res; 2017 Nov; 77(21):5846-5859. PubMed ID: 28720577 [TBL] [Abstract][Full Text] [Related]
9. LOXL2 induces aberrant acinar morphogenesis via ErbB2 signaling. Chang J; Nicolau MM; Cox TR; Wetterskog D; Martens JW; Barker HE; Erler JT Breast Cancer Res; 2013; 15(4):R67. PubMed ID: 23971878 [TBL] [Abstract][Full Text] [Related]
11. Novel mechanism for OSM-promoted extracellular matrix remodeling in breast cancer: LOXL2 upregulation and subsequent ECM alignment. Dinca SC; Greiner D; Weidenfeld K; Bond L; Barkan D; Jorcyk CL Breast Cancer Res; 2021 May; 23(1):56. PubMed ID: 34011405 [TBL] [Abstract][Full Text] [Related]
12. Lysyl Oxidase-Like Protein 2 Promotes Tumor Lymphangiogenesis and Lymph Node Metastasis in Breast Cancer. Wang C; Xu S; Tian Y; Ju A; Hou Q; Liu J; Fu Y; Luo Y Neoplasia; 2019 Apr; 21(4):413-427. PubMed ID: 30925417 [TBL] [Abstract][Full Text] [Related]
13. LOXL2 expression is associated with invasiveness and negatively influences survival in breast cancer patients. Ahn SG; Dong SM; Oshima A; Kim WH; Lee HM; Lee SA; Kwon SH; Lee JH; Lee JM; Jeong J; Lee HD; Green JE Breast Cancer Res Treat; 2013 Aug; 141(1):89-99. PubMed ID: 23933800 [TBL] [Abstract][Full Text] [Related]
14. Lysyl oxidase-like 2 is highly expressed in colorectal cancer cells and promotes the development of colorectal cancer. Cui X; Wang G; Shen W; Huang Z; He H; Cui L Oncol Rep; 2018 Aug; 40(2):932-942. PubMed ID: 29845296 [TBL] [Abstract][Full Text] [Related]
15. Emerging role of LOXL2 in the promotion of pancreas cancer metastasis. Park JS; Lee JH; Lee YS; Kim JK; Dong SM; Yoon DS Oncotarget; 2016 Jul; 7(27):42539-42552. PubMed ID: 27285767 [TBL] [Abstract][Full Text] [Related]
16. Escin Ia suppresses the metastasis of triple-negative breast cancer by inhibiting epithelial-mesenchymal transition via down-regulating LOXL2 expression. Wang Y; Xu X; Zhao P; Tong B; Wei Z; Dai Y Oncotarget; 2016 Apr; 7(17):23684-99. PubMed ID: 27008697 [TBL] [Abstract][Full Text] [Related]
17. Reduction of LOX- and LOXL2-mRNA expression in head and neck squamous cell carcinomas. Rost T; Pyritz V; Rathcke IO; Görögh T; Dünne AA; Werner JA Anticancer Res; 2003; 23(2B):1565-73. PubMed ID: 12820424 [TBL] [Abstract][Full Text] [Related]
18. A molecular role for lysyl oxidase-like 2 enzyme in snail regulation and tumor progression. Peinado H; Del Carmen Iglesias-de la Cruz M; Olmeda D; Csiszar K; Fong KS; Vega S; Nieto MA; Cano A; Portillo F EMBO J; 2005 Oct; 24(19):3446-58. PubMed ID: 16096638 [TBL] [Abstract][Full Text] [Related]
19. Pre-clinical evaluation of small molecule LOXL2 inhibitors in breast cancer. Chang J; Lucas MC; Leonte LE; Garcia-Montolio M; Singh LB; Findlay AD; Deodhar M; Foot JS; Jarolimek W; Timpson P; Erler JT; Cox TR Oncotarget; 2017 Apr; 8(16):26066-26078. PubMed ID: 28199967 [TBL] [Abstract][Full Text] [Related]
20. Lysyl oxidase-like 2 (LOXL2) controls tumor-associated cell proliferation through the interaction with MARCKSL1. Kim BR; Dong SM; Seo SH; Lee JH; Lee JM; Lee SH; Rho SB Cell Signal; 2014 Sep; 26(9):1765-73. PubMed ID: 24863880 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]